PRESS RELEASES

Alzheimer’s study seeks participants, aims to slow progression of disease.

​​

​

Read this story:

NBClinic participated in the Phase 2 clinical trial evaluating Neurocrine’s NBI‑1065845, showing promising results in MDD.

​

Read this study:

NBClinic was a participating site in the Phase 3 clinical trial demonstrating positive results for zuranolone in major depressive disorder.

​

Read this study:

Dr. Malhotra discusses the work being done at Neuro-Behavioral Clinical Research.

​​

​

Watch the Video  |  Read this story:

NBClinic actively participated in the Phase III clinical trials evaluating Fanapt’s efficacy for bipolar disorder.

​

Read this study:

NBClinic contributed as a clinical trial site in studies leading to the FDA approval of Qelbree for ADHD treatment.

​

Read this study:

NBClinic was a clinical trial site for Compass Pathways’ Phase 3 study of COMP360 psilocybin for treatment-resistant depression.

​

Read this study:

NBClinic served as a clinical trial site for the Phase 3 study of KarXT in schizophrenia, whose results were presented at ECNP.

​

Read this story:

NBClinic participated in the clinical trial leading to the FDA approval of Tonmya™ for fibromyalgia treatment.

​

Read this study: